Tumor immunotherapy has emerged as one of the most promising therapeutic methods to
treat cancer. Despite its clinical application, the immunosuppressive tumor …

Mounting evidence suggests that immunotherapies are a promising new class of anticancer
therapies. However, the immunosuppressive tumor microenvironment (TME), poor …

STING agonists have made great progress in tumor immunotherapy. However, the inherent
instability and low bioavailability have limited their wide applications. Herein, a reduction …

STING (stimulator of interferon genes) signaling pathway has attracted considerable
attention in cancer immunotherapy due to its capacity to boost vigorous antitumor immunity …

Insufficient activation of the stimulator of interferon genes (STING) signaling pathway and
profoundly immunosuppressive microenvironment largely limits the effect of cancer …

Therapeutic cancer vaccines require adjuvants leading to robust type I interferon and
proinflammatory cytokine responses in the tumor microenvironment to induce an anti-tumor …

Abstract cGAS-STING pathway, as an essential intracellular immune response pathway, has
attracted much attention in tumor immunotherapy. However, low metabolic stability of …

Activation of the stimulator of interferon gene (STING) pathway within the tumor
microenvironment has been shown to generate a strong antitumor response. Although local …

Due to the presence of natural neoantigens, autologous tumor cells hold great promise as
personalized therapeutic vaccines. Yet autologous tumor cell vaccines require multi‐step …

The response rate to PD-1/PD-L1 immune checkpoint inhibition (ICI) therapy in melanoma
remains low due to the immunosuppressive tumor microenvironment. Novel strategies …